Compass Ebit from 2010 to 2026
| CMPX Stock | USD 6.34 0.10 1.55% |
EBIT | First Reported 2019-06-30 | Previous Quarter -21.1 M | Current Value -14.3 M | Quarterly Volatility 9.6 M |
Check Compass Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Compass Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 8.8 M or Interest Income of 8.8 M, as well as many indicators such as Price To Sales Ratio of 187, Dividend Yield of 0.0 or PTB Ratio of 1.71. Compass financial statements analysis is a perfect complement when working with Compass Therapeutics Valuation or Volatility modules.
Compass | Ebit | Build AI portfolio with Compass Stock |
The evolution of Ebit for Compass Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Compass Therapeutics compares to historical norms and industry peers.
Latest Compass Therapeutics' Ebit Growth Pattern
Below is the plot of the Ebit of Compass Therapeutics over the last few years. It is Compass Therapeutics' EBIT historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Compass Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Ebit | 10 Years Trend |
|
Ebit |
| Timeline |
Compass Ebit Regression Statistics
| Arithmetic Mean | (43,272,478) | |
| Coefficient Of Variation | (28.82) | |
| Mean Deviation | 9,048,204 | |
| Median | (37,649,000) | |
| Standard Deviation | 12,472,496 | |
| Sample Variance | 155.6T | |
| Range | 54M | |
| R-Value | (0.52) | |
| Mean Square Error | 121.3T | |
| R-Squared | 0.27 | |
| Significance | 0.03 | |
| Slope | (1,281,256) | |
| Total Sum of Squares | 2489T |
Compass Ebit History
Other Fundumenentals of Compass Therapeutics
About Compass Therapeutics Financial Statements
Compass Therapeutics investors use historical fundamental indicators, such as Compass Therapeutics' Ebit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Compass Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| EBIT | -51 M | -53.5 M | |
| EBITDA | -49.4 M | -51.9 M | |
| Ebt Per Ebit | 1.00 | 1.06 | |
| Ebit Per Revenue | (59.96) | (62.95) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.